CODX Phase 2 readout: a negative outcome, -21.2%

On May 15, 2026, Co-Diagnostics, Inc. reached its Phase 2 readout. The result was a negative outcome, and the stock moved -21.2% in the window around the event. It had already run +21.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.